Last reviewed · How we verify
NCT07410455
An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome
Phase 2 trial testing Piclidenoson in Lowe Syndrome in 5 participants. Not yet recruiting.
31 August 2027
Quick facts
| Lead sponsor | Can-Fite BioPharma |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 1 June 2026 |
| Primary completion | 31 August 2027 |
| Estimated completion | 31 August 2027 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Piclidenoson — full drug profile →
Conditions studied
- Lowe Syndrome — all drugs for Lowe Syndrome →
Sponsor
Can-Fite BioPharma — full company profile →
Who can join
18 and older, male only, with Lowe Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this trial is to: 1\. Evaluate the efficacy of piclidenoson to increase renal uptake of 99mTc-labeled DMSA, in comparison to baseline, after 6 months (26 weeks) of treatment as a measure the reabsorption capacity of LMWPs by renal proximal tubules. The secondary objectives of this trial are to: 1. Evaluate changes in urinary excretion of LMWPs and other clinical parameters of renal Fanconi syndrome 2. Evaluate safety of piclidenoson in patients with Lowe syndrome
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07410455
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Piclidenoson
Trials testing the same drug.
- NCT04333472 — Piclidenoson for Treatment of COVID-19 · Phase 2 · completed
Other recruiting trials for Lowe Syndrome
Currently open trials in the same condition.
- NCT06065852 — National Registry of Rare Kidney Diseases · recruiting
Other Can-Fite BioPharma trials
Trials by the same sponsor.
- NCT06387342 — Namodenoson Treatment of Advanced Pancreatic Cancer · Phase 2 · recruiting
- NCT04697810 — Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) · Phase 2 · recruiting
- NCT04333472 — Piclidenoson for Treatment of COVID-19 · Phase 2 · completed
- NCT03168256 — CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis · Phase 3 · completed
- NCT02927314 — A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07410455 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Can-Fite BioPharma
- Last refreshed: 18 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07410455.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing